Anhui Huaren Health Pharmaceutical Co., Ltd. (301408.SZ) received shareholder approval on August 26 for its inaugural major refinancing initiative since its 2023 ChiNext listing, greenlighting a 709 million yuan private placement. The proposed capital deployment targets a regional sorting center construction project, pharmaceutical research and development, and an information systems upgrade, alongside a 150 million yuan allocation for working capital replenishment. This move refocuses market attention on the retail pharmacy operator's capital allocation strategy and growth trajectory.

The refinancing arrives even as the company retains unspent proceeds from its initial public offering, a detail that has drawn scrutiny. During the IPO phase, Anhui Huaren Health Pharmaceutical Co., Ltd. earmarked funds for building directly operated stores as the cornerstone of its marketing network expansion. The prospectus envisioned replicating its provincial success through organic store openings. However, the company pivoted decisively post-listing, redirecting a combined 176 million yuan originally designated for store construction into acquisitions. In November 2023, 45 million yuan was diverted to acquire a 60% stake in Zhoushan Liken Pharmaceutical. Then, in May 2025, an additional 131 million yuan was reallocated to purchase several regional pharmacy chains, including Fujian Yangzu Huimin, Fujian Haihua Pharmaceutical, and Hangzhou Guosheng Pharmacy. The cumulative effect left virtually all store-construction funds channeled into M&A activity.

The strategic shift carried notable valuation consequences. Appraisal reports revealed substantial premium multiples on acquired assets: Yangzu Huimin at 892.79%, Haihua Pharmaceutical at 1,029.40%, and Tonglu Yishengtang at a striking 2,350.84%. These premiums inflated consolidated goodwill to 1.282 billion yuan by the end of 2025, representing a staggering 61.16% of the company's 2.097 billion yuan net assets. This imbalance indicates that the bulk of shareholder equity derives from acquisition premiums rather than operational asset accumulation. The risk has already materialized, with 2025 goodwill impairment charges of 72.11 million yuan directly denting annual profits.

While altering fund usage is not uncommon among listed firms, Anhui Huaren Health Pharmaceutical Co., Ltd. justified the changes as necessary to enhance capital efficiency and align with its cross-regional development strategy. Industry analyses from securities firms highlight the pragmatic appeal of acquisitions over organic growth. Self-built stores typically face a 1鈥?year loss-making ramp-up period, compounded by weaker brand recognition in new markets, which depresses near-term margins. Acquiring established regional pharmacies offers immediate access to existing stores, local customer bases, and supply chain networks, accelerating market presence and revenue scale. UBS's 2026 pharmaceutical retail sector review noted that since the second half of 2024, many listed pharmacy chains have slowed self-built expansion, favoring M&A to fill regional gaps, albeit with the caveat that high premiums inflate goodwill and demand robust post-merger integration capabilities.

Investor inquiries on interaction platforms have pressed management on the earnings performance of acquired entities and goodwill mitigation measures. The company's responses remain general, citing annual third-party goodwill impairment tests and deferring specifics to periodic reports without disclosing target achievement rates.

This acquisition-led expansion mirrors a broader industry trend. Data from Choice, a financial data service, shows aggregate goodwill among major A-share listed pharmacy chains surpassing 20 billion yuan, with heavyweights like Laobaixing Pharmacy Chain, Yifeng Pharmacy Chain, and Dasanlin Pharmacy each carrying goodwill above 3 billion yuan. The historical logic was straightforward: fragmented regional markets invited consolidation, with listed chains leveraging capital markets to acquire local players, then applying centralized supply chains and standardized management to drive efficiency and profit growth.

However, the operating environment has soured. Medical insurance cost controls, centralized drug procurement, outpatient coordination policies, and online pharmacy competition have compressed gross margins, exposing the flaws of indiscriminate store-buying. Peer companies are showing the strain. Sinopharm Accord's subsidiary Guoda Pharmacy posted a 970 million yuan goodwill and intangible asset impairment in 2024, triggering substantial annual losses. Shuyu Pumin recorded 48.88 million yuan in goodwill impairment in 2024, sliding into a net loss. Jianzhijia contends with goodwill exceeding 90% of net assets, facing persistent impairment and guarantee pressures. China Merchants Securities' July 2026 tracking report declared the pandemic-era expansion dividend over, urging a shift from store-count metrics to evaluating per-store productivity, cash flow quality, and integration efficiency.

For Anhui Huaren Health Pharmaceutical Co., Ltd., the timing of this placement raises questions. With IPO funds still available and a 150 million yuan working capital component included, market observers debate the necessity of this raise. First-half 2026 results show revenue and profit growth, but operating cash flow fell 22.95% year-on-year, with debt-to-asset ratios holding above 60% and interest-bearing liabilities climbing, underscoring genuine liquidity constraints. Notably, this offering steers clear of store acquisitions, prioritizing instead sorting centers, IT systems, and R&D back-end capabilities 鈥?a strategic pivot toward strengthening infrastructure to support its existing network rather than continued territorial expansion.

This transition aligns with broader industry introspection: after substantial M&A sprees, the focus shifts to internal consolidation rather than rapid land-grabbing. Yet back-end infrastructure projects typically carry long investment cycles and slow returns, offering limited near-term profit contributions. The transformation's success will be tested against the backdrop of 1.282 billion yuan in goodwill, elevated debt, and cash flow realities. From an industry-wide perspective, M&A remains a viable strategy, but valuation frameworks have evolved. As Wanyuan Securities' research notes, while policy encourages pharmacy consolidation, market benchmarks now emphasize target quality, team integration, supply chain synergy, per-store profitability improvements, and goodwill risk management over sheer store counts or revenue size. Neither organic growth nor acquisitions holds absolute superiority: M&A delivers speed but demands paying premiums and managing integration risk; self-building offers control but moves slowly, with incubation periods weighing on short-term returns.